NXP-900 is under clinical development by Nuvectis Pharma and currently in Phase I for Medulloblastoma. According to GlobalData, Phase I drugs for Medulloblastoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NXP-900 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NXP-900 overview
NXP-900 is under development for the treatment of medulloblastoma, triple-negative breast cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, skin cancer, metastatic castration prostate cancer, pancreatic cancer, colon cancer, esophageal squamous cell carcinoma (ESCC), ovarian clear cell carcinoma, solid tumor and cholangiocarcinoma. It is administered by oral route. The drug candidate acts by targeting Src/Yes1 tyrosine kinase.
Nuvectis Pharma overview
Nuvectis Pharma is a biopharmaceutical company focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. Nuvectis Pharma is headquartered in Fort Lee, New Jersey, the US.
For a complete picture of NXP-900’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.